Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

By Chi‐Yuan Wu, L. Benet. Pharmaceutical Research, 2004

1,390 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology, Spectroscopy

View Paper: https://www.semanticscholar.org/paper/79ae0130e586c8dc13e2ae6e27d5b4c690666db6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

In Spectroscopy

Citations in the corpus

Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. (2011, background): “For instance, atenolol, cimetidine, and metformin are ategorized into this class (Wu and Benet, 2005).”
Advances in Oral Drug Delivery (2021, background): “For class 4 BDDCS drugs, predicting the effect of a high-fat meal on drug absorption is difficult, as a combination of interactions of both class 2 and 3 compounds is possible.”
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs (2007, background): “In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “4), originally developed by Amidon et al. (1995), with subsequent variations by others (Wu and Benet, 2005; Butler and Dressman, 2010; Chen et al., 2011).”
BDDCS Applied to Over 900 Drugs (2011, methodology): “Therefore, in proposing the BDDCS classification system, Wu and Benet (1) substituted extensive and poor metabolism for high and low permeability in the BCS while utilizing the same criteria as the FDA for high and low solubility.”
Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies (2007, background): “The unbound intracellular concentration may differ from that in the external medium due to transporter-mediated uptake; the consequences of this are not necessarily intuitive (Wu and Benet, 2005).”
Pharmacokinetics and dosage adjustment in patients with renal dysfunction (2008, background): “Recent work by Benet and colleagues has clearly shown that metabolic enzyme and transporter activities are interdependent and that this interplay significantly affects the systemic exposure of drugs cleared through non-renal routes [49, 82–85].”